Hepatitis viruses and hepatocellular carcinoma by Kew, Michael C.
personal communication).' There is little justification for the
use of immunoglobulin preparations in family contacts of
patients, as the donated serum is almost invariably from
First-World countries where most of the population has not
been exposed to HEY.' Hepatitis E is a self-limiting disease.
Liver biopsies taken years after the illness show no signs of
chronic disease.'·
Prevention
Hepatitis E is found worldwide but is particularly prevalent in
developing countries where living conditions, water supply
and solid waste disposal are poor.' Improved provision ~f
clean water and adequate sanitation reduce the spread of
HEY. The sequencing of the genome has provided valuable
information which could lead to the successful production of
a vaccine against this disease.
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Of the hepatitis viruses that have been identified and their
pathological consequences characterised, three - hepatitis
B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus
(HDV) - have been implicated as risk factors for
hepatocellular carcinoma (HCC) in humans. Sufficient _
evidence is now available to justify the conclusions that
chronic infection with HBV and HCV, but not HDV, are
causes of HCC. Hepatocellular carcinogenesis is a complex
step-wise process that evolves over many years, and the
precise way(s) in which these two viruses induce malignant
transformation remain uncertain. The observation that HBV
DNA is integrated into cellular DNA in the great majority of,
and perhaps all, HBV-related HCCs, whereas replicative
intermediates of HCV do not insert into host DNA in HCV-
related HCC, makes it very likely that different pathogenic
mechanisms operate in HBV- and HCV-indl,lced HCC.
Indeed, evidence is mounting that both direct and indirect
mechanisms, and often the two together, are involved in the
genesis of HBV-related HCC, but that HCV appears only to
induce HCC indirectly by causing chronic necro-
inflammatory hepatic disease which in turn is responsible for
tumour formation. There is some evidence that the two
viruses may interact in the development of HCC, but this
remains to be proven. Animal models - other members of
the hepadnavirus family (to which HBV belongs) that also
cause HCC in their respective animal hosts, and transgenic
mice into which sequences of HBV DNA have been inserted
- are proving useful in elucidating putative mechanisms of
HBV-related hepatocellular carcinogenesis, but no models
for studying HCV-induced HCC are yet available. Whatever
the pathogenesis of HBV-induced and HCV-induced HCC,
the viruses do not act alone but in conjunction with other
environmental carcinogens and a number of host factors.
Evidence ·for a causal role for
hepatitis viruses in HCC
HBV
The evidence linking chronic HBV infection to the
development of HCC is now well established and needs only
brief review.
1. With few exceptions, the geographical distributions of
the HBV carrier state and HCC, at both a global and a more
local level, parallel each other closely.'
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2. Individuals who become carriers of the virus at an early
age have a lifetime relative risk of developing HCC greater
than 100, and nearly 50% die from HCC, cirrhosis or both!
In regions with the highest incidences of HCC - sub-
Saharan Africa and parts of the Far East - infection with
HBV occurs in the first few months of life as a result of
either perinatal or horizontal transmission (about 90% of
children born to mothers with replicative HBV infection
become chronic carriers of the virus).' This group has the
greatest chance of developing HCC. The risk for those
infected as adults has not been formally ascertained, but it
is certainly substantially less than that recorded in early-
onset carriers.' This is illustrated, for example, by a recent
follow-up study of American military personnel who
developed acute B virus hepatitis during World War 11;
surprisingly few subjects progressed to chronic hepatic
disease and even fewer to HCC.3 Most of the approximately
300 million carriers of HBV worldwide acquire the infection
early in life.
3. The presence of the HBV carrier state almost always
precedes the onset of HCC by many years, an interval
commensurate with a cause-and-effect relationship between
the virus and the tumour.' The probability of HCC occurring
increases progressively with the duration of chronic HBV
infection.
4. Although the proportion of patients with HCC who
have markers of current HBV infection differs appreciably in
different geographical regions, the patients, whether in
regions with high, intermediate, or low incidences of the
tumour, consistently have a higher prevalence of these
markers than do appropriate controls.' Based on these data,
chronic HBV infection has been estimated to cause as much
as 80% of global HCC.
5. Almost all HCCs occurring in regions where the HBV
carrier state is endemic contain integrated sequences of
viral DNA.5
6. Indirect evidence for a causal link between HBV
and HCC is provided by the observation that other
hepadnaviruses also induce HCC in their respective hosts
(in woodchucks, with a frequency of close to 100% within
3 years of infection, and in ground squirrels, around 30%
within 5 - 6 years)."·7 Integrated sequences of hepadnaviral
DNA are present in cellular DNA in the tumours of both
these models."·7
HCV
Evidence of an aetiological role for HCV in HCC is more
recent but nevertheless persuasive. The first hint of an
association between chronic HCV infection and the
occurrence of the tumour was provided by isolated reports
of patients·'12 (and a chimpanzee") with transfusion-acquired
non-A, non-B hepatitis who, over a period of many years
developed, in turn, chronic hepatitis, cirrhosis, and finally
HCC (serum from some of these patients, but not the
chimpanzee, was later used to verify infection with HCV).
With the recent availability of serological tests for HCV, it has
become possible to investigate the association between
HCV and HCC more thoroughly. First-generation enzyme-
linked assays, which detected antibody to a single HCV
epitope (C-1 00), were of limited specificity and sensitivity,
and were soon superseded by assays which recognise
additional antibodies against both structural and non-
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structural HCV epitopes and reflect more reliably the
presence of anti-HCV in serum. Furthermore, recombinant
immunoblot assays (RIBAs) are now used as confirmatory
tests. More recently, HCV RNA in serum and tissues was
amplified by means of the polymerase chain reaction (after
the RNA was converted to DNA with reverse transcriptase);
properly done, this method provides the most accurate -
although not infallible - means of evaluating the closeness
of the correlation between persistent HCV infection and the
formation of HCC..
As is true of HBV, the proportion of patients with HCC
who have circulating anti-HCV shows a pronounced
geographical variation. In Japan,'··'6 which has a high
incidence of HCC, and in Italy17.1. and Spain,"·20 with
intermediate incidences, between 47% and 83% of the
patients with HCC have circulating anti-HCV. The relative
risk for HCC in Japanese with persistent HCV infection is
52,3 (95% confidence interval 23,9 - 114,3)15 and in Italians
69,1 (15 - 308).'· These risks are 3 - 4 times higher than
those for chronic HBV infection in the same populations,
and markers of current HBV infection are present in only
20 - 25% of these patients. During recent decades the
incidence of HCC in Japan has increased substantially, and
this has been attributed to an increasing frequency of
chronic HCV infection in this population."
In those geographical regions where HBV infection is
endemic and this virus is the major risk factor for HCC, anti-
HCV is present in the serum of only a minority of patients
with the tumour - in Far Eastern countries between 6% and
39%,22-26 and in sub-Saharan Africa 20%.27 Relative risks in
these populations were calculated to be 7 (1,6 - 30,8) in
Taiwan" and 6,1 in Senegal (0,5 - 69).'· Comparatively low
prevalences of anti-HCV (13 - 35%)29.35 have also been
recorded in the remaining regions for which information is
available. Relative risks in these populations are 10,4 (4,2 -
26) in Greece29 and 10,5 (3,5 - 31,3) in North America.35
These prevalences and risks are similar to those for HBV in
these regions. The global pattern of HBV- and HCV-related
HCCs is shown in Fig. 1.
Fig. 1. The pattern of HBV-induced and HCV-induced
hepatocellular carcinoma in different geographical regions and
populations. The dark grey stippled portion of the pie diagrams
represents aetiological factors other than HBV and HCV.
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Two longitudinal studies of the risk of HCC developing in
patients with HCV-related chronic benign hepatic disease
have been published. Sixty-two Japanese patients with
chronic hepatitis, whose serum was positive for anti-HCV
and who were not alcoholics, were observed for at least 5
years.36 Sixteen patients (25,8%) developed HCC during this
time. Of these, 13 progressed to cirrhosis and 3 remained
with chronic hepatitis. No control group was included.
Patients with chronic benign hepatic disease with and
without circulating anti-HCV were monitored in Sweden for
up to 1"1 yearsY The proportion of deaths from HCC was
significantly higher in the anti-HCV-positive (18%) than in the
anti-HCV-negative patients (4%). In a follow-up of 568
subjects who had had acute post-transfusion non-A, non-B
hepatitis (no anti-HCV testing was done) and 968 matched
controls a mean of 18 years after being transfused, only 1
case of HCC was uncovered in the hepatitis group and 2
among the controls (relative risk 1,0).38 This finding may not
be valid because of the relatively short period of follow-up
after acute hepatitis.
HDV
There is at present no convincing evidence of a causal role
for HDV in HCC. Only 3 case-control studies of the .
seroprevalence of antibody to the Delta antigen (anti-HDV) in
patients with HCC have been documented (although 14
case series have been published), and none of the 3 showed
the presence of anti-HDV to be a risk factor for tumour over
and above that attributed to concurrent chronic HBV
infection.39-41 One possible explanation is that patients with
combined HBV/HDV infection have such severe chronic
necro-inflammatory hepatic disease that they die before
HCC has had time to develop!2
Age and gender differences in
HBV- and HBC-virus-induced
HCC
In regions where HBV infection is endemic, HCC occurs at a
younger age in patients with HBV-related tumours than in
those with HCV-related tumours!',27,'" The mean age of
Taiwanese patients with anti-HCV-positive HCC is 65,1 ± 6
years compared with 55,5 ± 11,9 years in those with
HBsAg-positive HCC;'" in southern African blacks the
corresponding figures are 52,3 years (range 37-78 years)
and 40,3 years2? (17 - 80 years), and in Hong Kong Chinese
the mean difference is 7 years!4 Significant age differences
have also been recorded in some countries with a lower
prevalence of the HBV carrier state: anti-HCV-positive
patients in Japan have a mean age of 62,7 ± 8,6 years
compared with 55,9 ± 9,6 years in HBsAg-positive patients",
and in the USA the corresponding figures are 59 years
(range 24 - 76 years) and 44 years (32 - 52 years)." One
possible explanation for these age differences is that, in
these populations at least, HCV infection is acquired later in
life than is chronic HBV infection. In other countries no age
difference was apparent."·19 The co-existence of HBV and
HCV infections in patients with HCC does not, at least in
Taiwanese patients, accelerate the rate of tumour
development in comparison with HBV infection alone.'"
In most reports no difference in anti-HCV positivity rates
was evident between men and women with HCC.1719...
However, in one Japanese" and one Italian'" study,
circulating anti-HCV was present significantly more often in
males, and in an analysis from the west coast of the USA
the relative risk of HCC developing in anti-HCV-positive men
(19,6) was appreciably greater than in anti-HCV-positive
women (5,1).35 Anti-HCV-positive HCC may be relatively more
common than HBsAg-positive HCC in women in Hong Kong
(female/male ratio -1:7 compared with 1:11)2' and in the
USA (1 :6,7 compared with 0%:100%)." This appeared also
to be true in southern African blacks when they were tested
with a first-generation assay'", but was not confirmed Ln a
later study with a second-generation assay and






Evidence continues to accumulate that both direct and
indirect mechanisms are involved in HBV-induced
hepatocellular carcinogenesis.
Direct carcinogenicity
Although HBV-related HCC often co-exists with cirrhosis"
(and sometimes with chronic hepatitis), in a proportion of
patients the tumour arises in an otherwise normal liver, and
it is in these patients that a specific carcinogenic effect is
most likely. Moreover, in populations with a high incidence of
HBV-related HCC, HBsAg is present in serum and hepatic
tissue as often in those HCC patients without cirrhosis as in
those with co-existing cirrhosis.....9The fact that
woodchucks chronically infected with woodchuck hepatitis
virus (WHV) show a gradual transition from preneoplastic
nodules to fully developed HCC in the absence of cirrhosis
or chronic hepatitis proVides further, albeit indirect, support
for a direct mechanism.50
The HBV genome does not contain a known oncogene,
and the long interval between jnfection and the appearance
of HCC confirms that HBV does not code for an acutely
transforming protein. However, the detection of HBV DNA
integrants in host DNA in about 85% of reported HBV-
related HCCs (95% in regions where HBV and HCC are
common)5 is consistent with the mechanism of
tumorigenesis described with non-acutely transforming
viruses, namely insertional mutagenesis. Integration could
even be invariable in these tumours: cellular DNA flanking
HBV DNA inserts often becomes grossly rearranged as a
result of deletions, duplications, amplifications and
translocations, and in those tumours without HBV DNA the
integrant or integrants could subsequently have been lost as
a result of deletion. Such an occurrence would imply that
integrated HBV DNA, even if essential for the initiation of
hepatocellular carcinogenesis, is not needed for the
maintenance of the transformed phenotype ('hit-and-run'
hypothesis). Other integrants could be too short to be
detected by current methods.
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Insertion of HBV DNA into cellular DNA appears to occur
at random sites, although some chromosomes are affected
more often than others.51 This observation argues against
integration, either in or near the regulatory elements of a
proto-oncogene (or other gene concerned with cell growth,
cycling or differentiation) or within a tumour suppressor
gene, being a numerically important way of inducing
malignant transformation of hepatocytes. Indeed, there are
very few reports in the literature of HBV DNA integration
near a growth regulatory gene52,53 and none of disruption of a
tumour suppressor gene in human HCCs. Because most
HCCs contain multiple integrants and these studies have
been undertaken only when a single integrant was present,
and because other genes adjacent to sites of viral insertion
may yet prove to be growth regulatory or tumour suppressor
genes, the frequency of direct insertional mutagenesis may
be underestimated. indirect support for the potential
importance of this mechanism is the finding that in about
50% of HCCs in woodchucks infected with WHV, integration
takes place within regulatory sequences of c-myc or N-myc
2; this leads to activated expression of these genes.54.55
Furthermore, transgenic mice into which the woodchuck
c-myc gene in tandem with upstream WHV DNA has been
directly inserted, develop HCC.5S However, when ground
squirrels infected with ground squirrel hepatitis virus were
studied by the same laboratory, none of the integrants was
found to be in the region of c-myc or N-myc 2 (W. S.
Robinson and P. Tiollais - personal communication), so that
the relevance of the finding to human HCC is difficult to
assess. Moreover, in a transgenic mouse model expression·
analysis of all proto-oncogenes and tumour suppressor
genes thus far known to be associated with hepatocellular
carcinogenesis failed to reveal any qualitative or quantitative
alteration.57 Activated c-myc, N-ras and c-fos expression
have been reported in human HCCs, but expression of these
oncogenes is increased during hepatic regeneration and
these changes may be a consequence rather than the cause
of cellular proliferation in the tumour.58 Nevertheless,
mutations of codon 6 of N-ras and codon 12 of H-ras have
occasionally been reported. 51 ,5'
Unique fusion proteins encoded by adjacent virus and
host DNA sequences and having transforming properties
play a crucial role in retrovirus-induced cancers. so Such
fusion proteins have, however, not been detected in human
HCCs. Although there is no proof that insertion of HBV DNA
has directly resulted in disruption of tumour suppressor
genes, loss of heterozygosity on chromosomes 4q, 11 P and
17p (including some in the region of the p53 tumour
suppressor gene) has been described in relation to HBV
integration.s1 Loss or disruption of chromosomal DNA
secondary to viral integration may also have effects on the
expression of proto-oncogenes or tumour suppressor genes
remote from the site of integration.62,53
Integrated HBV DNA may induce malignant transformation
in another way. The product of the HBV X gene can activate
in trans a wide variety of viral and cellular promoters,
thereby perturbing the expression of cellular genes and the
differentiated functions of the infected cell in such a way as
to lead ultimately to malignant transformation of the cell.64•65
Evidence in support of this putative mechanism has recently
been published. The entire X gene, under its own regulatory
elements, was placed into the germline of mice. The
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transgenic mice harbouring the gene developed, in turn,
multifocal areas of altered hepatocytes, benign hepatic
adenomas and finally malignant carcinomas, all of this in the
absence of chronic necro-inflammatory hepatic disease."
This sequence of events is the same as that described in
experimental chemical carcinogenesis, and suggests that
abnormal expression of cellular genes may initiate aberrant
growth. The X gene, in toto or in a 3' truncated form, is often
included in HBV DNA integrants, and could express X
polypeptides or X-cellular fusion proteins.57." Three truncated
preS/S genes have also been shown to have trans-activating
properties." (This region is most often included in HBV DNA
integrants.5) Activation or inactivation of growth regulatory
genes in hepatocellular carcinogenesis, whether in Gis or in
trans, remains an attractive hypothesis because either could
confer upon initiated hepatocytes a growth advantage
which, coupled with an opportunity for selection, would
generate cells that are at risk for further genetic events in
the multistep process of tumour formation.
Insertion of HBV DNA into cellular DNA has not, however,
been proved to be an essential first step in virally-induced
carcinogenesis. If extra-chromosomal DNA can be directly
carcinogenic, the way in which this would be accomplished
is not known. On the other hand, integration is not
synonymous with malignant transformation because HBV
DNA integrants have been detected in cirrhotic nodules.'o
Neither is it known if HBV can cause HCC in the absence of
other environmental carcinogens. The most convincing
evidence that it can is indirect: woodchucks infected with
WHV as neonates develop HCC even when reared in an
environment free of known carcinogens." The only evidence
in humans is the observation that HBsAg-positive mentally
deficient children growing up in an institution in California,
USA, in the absence of aflatoxin and other known chemical
carcinogens, have a relative risk for HCC of more than 200."
Of significance also was the observation that these tumours
arose in the absence of cirrhosis.
Indirect carcinogenicity
The majority of HCCs throughout the world co-exist with
cirrhosis." Moreover, all forms of cirrhosis, whatever their
cause, may be complicated by HCC."Accordingly, cirrhosis
per se is regarded as a major risk factor for HCC. In studies
carried out in the UKn and Austria,'3 both of which have a
low incidence of HBV-related HCC, cirrhosis (as well as male
sex and the ages of the patients), but not the presence of
HBsAg, proved to be a risk factor for HCC. Indirect evidence
for an important role for chronic necro-inflammatory hepatic
disease and the resulting hepatocyte regeneration in the
pathogenesis of HCC is provided by the transgenic mouse
model described by Chisari et al." In this experiment the
region of the HBV genome encoding for the surface and
presurface proteins was inserted directly into the germline of
mice. These mice overproduce large-envelope (preS1)
protein, which accumulates in the endoplasmic reticulum of
hepatocytes producing severe and prolonged hepatocyte
injury that initiates a response characterised by
inflammation, regenerative hyperplasia and transcriptional
dysregulation, with ultimate progression to neoplasia. This
finding supports the notion that continuous or recurrent
regeneration of hepatocytes caused by persistent HBV
infection provides an opportunity for the selection of cells
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that possess some growth advantage, a crucial step in the
promotion of tumour development.
Carcinogenesis is a complex step-wise process, and
hepatocellular carcinogenesis is no exception. Because
HCC is closely associated with chronic HBV infection rather
than HBV infection per se, the molecular genetic events
essential to HCC formation must be related to continuous or
recurring cycles of viral infection. Indeed, it is very likely that
indirect and direct effects of HBV act together in the
induction of most HBV-related HCCs. The increased
hepatocyte turnover rate, resulting from continuous or
recurring cycles of viral infection with consequent cell
necrosis and regeneration, increases the likelihood both of
viral integration and of the resultant changes in DNA ~eing
'fixed' in the daughter cells, as well as providing an
opportunity for the selective growth advantage of the
initiated cells to be exercised. Another possible way in which
indirect and direct carcinogenic effects may interact
concerns the enzyme topo-isomerase I. This cellular enzyme
alters the superhelical state of DNA by nicking-closing
reactions on single- and double-stranded DNA75.'. With
double-stranded DNA there is no resultant conformational
change, but when the DNA is single-stranded topo-
isomerase I cleavage causes linearisation of the DNA.
Topo-isomerase I has been shown to b~ capable of
generating WHV DNA integration into cellular DNA in vitro. n
Intracellular concentrations of the enzyme are increased
during cell replication. 78 Thus, the accelerated cell turnover
rate accompanying virally-induced chronic necro-
inflammatory hepatic disease may, by enhancing topo-
isomerase I activity, result in cleavage of viral DNA at
specific sites and promote its insertion into cellular DNA
There is also epidemiological evidence that favours a
combination of carcinogenic effects in that HCC is far more
likely to occur in cirrhotic patients who are HBsAg-positive
than in those who are HBsAg-negative,'9 and in HBV carriers
with cirrhosis or chronic hepatitis than in those without
chronic hepatic disease.5O Furthermore, the occurrence of
HBV-related HCC in children is linked to the rapid
development of cirrhosis.8t
HCV
The pathogenesis of HCV-induced HCC is unknown.
Although HCV, a positive-stranded RNA virus, has been
shown to replicate in HCC tissue,82 there is as yet no
evidence that replicative intermediates of the viral genome.
become integrated into host DNA If this observation is
confirmed, insertional mutagenesis can be excluded as a
pathogenic mechanism. Nor is there, at present, any
evidence that HCV genes have trans-activating properties.
Based on current knowledge, it thus seems unlikely that
HCV is directly carcinogenic. This conclusion is supported
by the fact that no well-documented case of HCV-induced
HCC arising in a normal liver has yet been reported. In
published series the non-tumorous hepatic tissue in the
great majority of these patients has been cirrhotic and the
remainder have had chronic hepatitis. A few reports - on
Italian'8.45 and TaiwaneseB3 patients - have stated that a
small proportion of the anti-HCV-positive patients with HCC
have not had cirrhosis, but the authors failed to mention
whether the non-neoplastic tissue showed chronic hepatitis
or was normal. However, in one report on Italian patients,
the authors write that 'a few' patients with HCC and a
normal liver had circulating anti-HCV detected by a first-
generation assay." Infection with HCV is often complicated
by progression to chronic hepatitis and cirrhosis. 85 Taken
together, these observations strongly support the notion that
HCV acts indirectly in the pathogenesis of HCC, Le. that
chronic HCV infection causes chronic necro-inflammatory
hepatic disease and it is this rather than the presence of the
virus per se that is reponsible for subsequent tumour
formation. Ongoing or recurrent virally-induced hepatocyte
necrosis and regeneration increase cell turnover rates,
thereby rendering the DNA more susceptible to spontaneous
or mutagen-induced changes.
Because the great majority of HCV-rel~tedHCCs arise 'in
cirrhotic livers:' the question arises whether chronic HCV
infection enhances the risk of the development of HCC in
cirrhotic livers, whatever their cause. Simonetti et al. 18
showed anti-HCV to be present in 74% of Italian patjents
with HCC and cirrhosis but in 62% of those with cirrhosis
alone (odds ratio 1,8; range 1,1 - 2,8). They concluded that
HCV increases the risk of HCC in patients with cirrhosis,
irrespective of the aetiology. Caporaso et a/. 86 found
circulating HCV (as well as age and male sex) to be a risk
factor for HCC in Italian patients with cirrhosis. Anti-HCV
was present significantly more often in Spanish patients with
alcoholic cirrhosis and HCC (54%) than in those with
alcoholic cirrhosis alone (24%),8' but there was no difference
in patients with cryptogenic cirrhosis.'9 Similar findings in
respect of alcoholic cirrhosis were reported in French
patients,BB although in a multidimensional analysis of risk
factors for HCC in French patients with alcoholic cirrhosis,
anti-HCV seropositivity proved to be only weakly associated
with tumour formation.B9 These findings imply that HCV may
play a role in inducing HCC formation in cirrhotic livers that
have resulted from alcohol abuse, although the evidence in
respect of other aetiological forms of cirrhosis is equivocal.
Possible interaction of HBV and
HBC in the genesis of HCC
An interaction, if any, between HBV and HCV in
hepatocellular carcinogenesis remains uncertain. Most early
studies showed circulating anti-HCV to be present
appreciably more often in HBsAg-negative than in HBsAg-
positive patients with HCC.14.'5,21.32.43....B3... Similarly, in a recent
analysis of black Africans the prevalence of current HBV
infection was significantly lower in patients positive for HCV
viraemia than in those who were negative!' These
observations suggested that HCV was particularly likely to
be a causative factor in patients in whom HBV could not be
implicated. However, other case series and case control
studies have not shown a difference."·19.8' In only a few
reports have relative risks for HCC in individuals positive for
anti-HCV alone, HbsAg alone, and the two together been
calculated. In a study of anti-HCV-positive Greek patients,
which permitted the examination of mutual confounding and
interactive effects between HCV and HBV, Kaklamani et a/. 90
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calculated a relative risk for HCC of 20 in HBsAg-positive
subjects compared with only 4,8 in those without this
marker. This confirmed an earlier observation from the
USA.35 The relative risk for HCC in Taiwanese subjects
positive for both HBV and HCV was 40, compared with 14
in carriers of HBV alone and 27,1 in carriers of HCV alone."
Using a slightly different approach, Yuki et al. 16 assayed for
anti-HCV in Japanese carriers of HBV, some of whom
suffered from HCC. The antibody was present substantially
more often in the carriers with tumour (32%) than in those
without (5%). Assuming that HCV infection is usually
acquired earlier in life than is HBV infection, these studies
suggest that HCV superinfection in HBV carriers increases
the risk of HCC development. However, in a report of Italian
patients multivariate conditional logistic regression showed
that HCV and HBsAg act as completely independent risk
factors'S Neither could a statistically significant synergism
between markers of HCV and HBV be found in French
patients with HCC.88 These discrepant findings may result
from the small numbers of patients with both HCV and HBV
serological markers included in the studies. Larger analyses
in regions with different rates of chronic infection with HBV
and HCV will be required in order to determine if there is an
interaction between the two viruses in the genesis of HCC.
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The laboratory diagnosis of
acute viral hepatitis
C. W. Spearman
The definitive diagnosis of viral hepatitis depends on the
demonstration of the virus or of serological markers of
recent infection. The serological tests to establish the
aetiology of viral hepatitis vary from laboratory to laboratory.
Those commonly performed are discussed here. An _
algorithm (Fig. 1) is provided as a guide to the investigation
of patients with suspected hepatitis. It is stressed that the
choice of initial tests should be based on the clinical
findings in each individual patient.
Hepatitis A
Hepatitis A virus (HAV) or viral antigen can be detected in
stool and other body fluids by various techniques including
electron microscopy and molecular hybridisation to
radiolabelled cDNA probes or single-stranded RNA (viral
RNA) probes. However, these techniques are time-
consuming and expensive. By the time the patient presents
with symptoms, the infection is established and the
diagnosis is thus based on the detection of specific
antibodies to HAV by radio-immunoassay (RIA)' or enzyme-
linked immunoassay (ELlSA)?
IgM anti-HAV antibodies are detectable in the serum at
the onset of symptoms, the titres rise rapidly and may
persist for 48 - 60 days after the onset of symptoms. False
positives are rare. The presence of HAV IgG antibody alone
indicates previous exposure and thus immunity, and
excludes current infection.
Hepatitis B
Commercially available tests for the diagnosis of hepatitis B
virus (HBV) infection include tests for the detection of
HBsAg, HBeAg, HBV DNA (by hybridisation techniques),
anti-HBs, anti-HBe, IgM anti-HBc and IgG anti-HBc. For
research purposes, tests are available to detect HBV DNA
by polymerase chain reaction (PCR), HBV DNA polymerase
activity, pre-S, and pre-S2 antigens and their antibodies.
In acute hepatitis B, HBsAg is detectable during the
prodromal phase prior to the elevation of transaminases.
Although the presence of HBsAg in the serum implies active
infection, the absolute level has no clinical significance and
does not correlate with the degree of infectivity.' However, in
an individual patient, a decreasing HBsAg titre is indicative
of a resolving infection. In a minor infection, HBsAg is
cleared rapidly and the only evidence of infection may be
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